Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study
J Eur Acad Dermatol Venereol, 2020.
Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM; BADBIR Study Group.
Read publication: J Eur Acad Dermatol Venereol
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for ps...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
0 Comments